Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Blood Cancer Discovery|October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.Research Square|June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple MyelomaMalin Hultcrantz, Hani Hassoun, Neha Korde, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.Blood Cancer Discovery|October 15, 2021
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.Nature Cancer|November 9, 2023
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimensFrancesco Maura, Eileen M Boyle, David Coffey, et al.Blood Cancer Discovery|June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestryKylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.The New England Journal of Medicine|September 28, 2022
GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Sean M Devlin, Jonathan Landa, et al.Pageof 8